We investigated the influence of acute hypoxia on the placental vascular endothelial growth factor system in vitro and in vivo in acute birth asphyxia compared with pregnancies that were complicated by preeclampsia and with healthy control subjects. STUDY DESIGN: Messenger RNA levels for vascular endothelial growth factor, flt-1, and KDR were measured by TaqMan real-time polymerase chain reaction in human placental choriocarcinoma cells (BeWo) that were exposed to hypoxia (1% oxygen, 5% carbon dioxide, 94% nitrogen) and in placental tissue of neonates with birth asphyxia (n = 20), newborn infants of mothers with preeclampsia (n = 20), and gestational age-matched control subjects. Immunhistologically, placental vascular endothelial growth factor protein expression was compared among the groups. RESULTS: In BeWo cells, vascular endothelial growth factor, flt-1 and KDR messenger RNA increased in a time-dependent manner in response to hypoxia. In vivo, vascular endothelial growth factor/β-actin and KDR/β-actin messenger RNA were significantly higher in placental tissue of newborn infants with severe hypoxic-ischemic encephalopathy than with newborn infants with mild or no hypoxic-ischemic encephalopathy and control subjects. In chronic placental hypoxia (preeclampsia), vascular endothelial growth factor and both receptors were found to be up-regulated. Increased placental vascular endothelial growth factor expression was confirmed by immunohistologic examination. CONCLUSION: The vascular endothelial growth factor system is up-regulated in response to placental hypoxia and is assumed to be a potential early indicator of severe birth asphyxia. (Am J Obstet Gynecol 2003;188: 517-23.) 
A number of hypoxia inducible genes and their protein products have been shown to be involved in uteroplacental and fetal angiogenesis and vasculogenesis, placental energy metabolism, and cell proliferation. 1, 2 Vascular endothelial growth factor (VEGF), a polypeptide growth factor that is activated by tissue hypoxygenation, 1,3 acts through two high-affinity receptor tyrosine kinases (VEGFR), fms-like tyrosine kinase (flt-1, VEGFR-1) and kinase-insert domain-containing receptor (KDR/Flk-1, VEGFR-2). 4, 5 In human term placenta, VEGF protein 6 and VEGF messenger RNA (mRNA) 7 were found to be expressed primarily by the villous trophoblast and syncytiotrophobast. Flt-1 mRNA is detected mainly in the syncytiotrophoblastic layer and, at lower levels, in the villous trophoblast; KDR mRNA is detected mainly in vascular endothelial cells of the placenta and decidua. 8, 9 Binding of VEGF to flt-1 activates endothelial tube formation; binding to KDR stimulates endothelial cell proliferation, microvascular permeability, chemotaxis, and antiapoptotic proteins. 4, 5, [10] [11] [12] Although the expression of VEGF mRNA and protein content is influenced by several growth factors and cytokines, tissue hypoxia is thought to be the major stimulating factor for the up-regulation of VEGF in vivo. 13 In preeclampsia that is associated with compromised placental vascular development and oxygen delivery, increased expression of VEGF and flt-1 has been shown in placental syncytiotrophoblasts. 8 Results on the expres-sion and function of VEGF receptor in response to tissue hypoxygenation are contradictory. 14, 15 In vivo data on the placental regulation of the VEGF system in acute perinatal hypoxia (such as birth asphyxia, a well-known risk factor of increased perinatal morbidity and central nervous system damage) are not available.
The first objective of this study was to investigate placental mRNA expression of VEGF and its receptors flt-1 and KDR in response to acute hypoxia in vitro and in vivo compared with prolonged hypoxic ischemia in vivo. The second objective was to examine the relationship between the regulation of the VEGF system and the clinical degree of hypoxic-ischemic encephalopathy (HIE) in birth asphyxia.
Material and methods

In vitro investigations.
Human trophoblast choriocarcinoma cells (BEWO, DSMZ No ACC 458) were obtained from the German Collection of Microorganisms and Cell Cultures (Department of Human and Animal Cell Cultures, Braunschweig, Germany). The cells were incubated at 37°C under either normoxic standard tissue culture condition (5% carbon dioxide, 95% air) or hypoxic condition (1% oxygen, 5% carbon dioxide, 94% nitrogen) for 1, 2, 4, 16, 12, and 24 hours. Three experiments per hypoxia period were carried out. The cells were cultured in 85% Ham's F12 medium supplemented with 15% fetal bovine serum, 2 mmol/L L-glutamine, and 1% penicillin/streptomycin. The cells were grown to 80% to 90% confluency (as monolayer). After 24 hours, all cultures were still 80% to 90% confluent. After a given incubation period, the cells were immediately stored at -80°C until isolation of total mRNA.
In vivo protocol. The study was approved by the local ethics committee of Friedrich-Alexander University, and standardized informed consent was obtained by the parents. Immediately after delivery, three placental tissue specimens were obtained after removal of the amniotic membrane and maternal decidua, were shock frozen, and were stored at -80°C until isolation of total RNA and immunohistologic investigation. Placental tissue was collected from (1) normal term deliveries without prenatal or intrapartal complications and normal Apgar index/blood gas analysis (pH, >7.20; n = 15 deliveries) and (2) preterm deliveries because of premature labor without complications, except immaturity (n = 8 deliveries). (3) Placental tissues from asphyxiated newborn infants were selected according to the following criteria: gestational age ≥36 weeks, cord blood pH <7.10, and base deficit ≥10 mEq. The classification of HIE was performed according to the criteria of Sarnat and Sarnat. 16 Newborn infants with congenital malformations, genetic disorders, or inborn errors of metabolism were excluded. (4) Preeclampsia (n = 20 women) was defined according to international criteria. 17 Women with nicotine abuse, drug administration, or preexisting hypertension were excluded. Clinical data are summarized in Table I .
TaqMan real-time polymerase chain reaction. RNA was isolated with the use of the RNAzol-B isolation kit (WAKChemie Medical GmbH, Bad Homburg, Germany). Quantitative real-time reverse transcriptase-polymerase chain reaction was used to monitor gene expression. This method, which has been described previously, 18 makes use of the 5´ exonuclease activity of the DNA polymerase (AmpliTaq Gold). Within the amplicon that is defined by a gene-specific polymerase chain reaction (PCR) primer pair, a oligonucleotide probe that is labeled with two fluorescent dyes is created (TaqMan probe). As long as the probe is intact, the emission of the reporter dye (ie, 6-carboxy-fluorescein [FAM] ) at the 5´-end is quenched by the second fluorescence dye (6-carboxy tetramethylrhodamine [TAMRA]) at the 3´-end. During the extension phase or PCR, the polymerase cleaves the TaqMan probe, which results in a release of reporter dye. The increasing amount of reporter dye emission is detected by an automated sequence detector that is combined with a special software (ABI Prism 7700 Sequence Detection System; Perkin-Elmer Corp, Foster City, Calif). The algorithm Data are presented as mean ± SEM (range). *P < .005 by one-way analysis of variance.
normalizes the reporter signal to a passive reference. Next, the algorithm multiplies the SD of the background reporter signal in the first few cycles (in most PCR systems, cycles 3-15, respectively) by a default factor of 10, to determine a threshold. The cycle at which this baseline level is exceeded is defined as threshold cycle. The threshold cycle depends on the initial template copy number and on the efficiency of both the DNA amplification and the cleavage of the TaqMan probe. The threshold cycle values of the samples are interpolated to an external reference curve that is constructed by plotting the relative or absolute amounts of a serial dilution of a known template versus the corresponding threshold cycle values. Commercial reagents (TaqMan PCR Reagent Kit, Perkin-Elmer Corp) and conditions were applied according to the manufacturer's protocol. A total of 2.5 µL of complementary DNA (reverse transcription mixture) and oligonucleotides at a final concentration of 300 nmol/L of primers and 200 nmol/L of TaqMan hybridization probe were analyzed in a 25-µL volume. The oligonucleotides of each target of interest were designed by the Primer Express software (Perkin-Elmer Corp) with the use of uniform selection parameters that allow the application of standard cycle conditions. VEGF, KDR, and flt-1 gene expression was related to the mRNA expression of two housekeeping genes, β-actin and porphobilinogen deaminase (PBGD). VEGFR-2 (KDR). Forward: 5´-CGGCAAATGTGTCAGCTTTG -3´; reverse: 5´-CACGTGGAAGGAGATCACCC-3´; TaqMan probe: 5´(FAM)-AGCGGTCAACAAAGTCGGGAGAGGAG -(TAMRA)-3´, The thermocycler parameters were 50°C for 2 minutes (for carryover prevention with uracil-N-glycosylase), 95°C for 10 minutes (for hot start PCR), followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.
Immunhistological analysis. For immunohistochemistry, 5 µm-thick frozen sections were cut, fixed in acetone (10 minutes at -20°C), and dried (overnight at room temperature). After being washed and blocked Semiquantitative evaluation of VEGF staining in stem vessels and in the stroma of intermediar and end villi was performed with a four-grade scale by an observer who was blinded to the study groups: 0, no detectable staining; 1, weakly detectable staining; 2, moderate staining; and 3, very strong intensity staining.
The possible influence of different numbers of blood vessels between hypoxic and control tissues on VEGF expression could be excluded by immunohistochemical investigation of endothelial cell marker CD31 (CD31 monoclonal antibodies; Dako Diagnostika GmbH; data not shown).
Statistical analysis. Data are expressed as mean ± SEM, except the results of semiquantitative scoring, which are given as median (range). Statistical significance was determined by one-way analysis of variance and by two-way analysis of variance (for repeated measurements). In cases of significance, a post hoc test was performed. Semiquantitative data were compared with the use of the Kruskal-Wallis test. A probability value of <.05 was regarded as significant.
Results
In BeWo cells, a significant increase of VEGF/β-actin mRNA expression occurred within 12 hours under hypoxia, with a further increase up to 24 hours (P < .005). KDR/β-actin and flt/β-actin mRNA increased, but not before 24 hours of hypoxia (P < .005) (Figs 1 and 2) .
Messenger RNA of VEGF, flt-1, and KDR was expressed in all placentas of gestational age between 27 to 41 weeks. In healthy deliveries, placental VEGF gene expression was not correlated significantly to gestational age, placental weight, or newborn infant weight (Table I) . We found no significant difference in flt-1/β-actin mRNA and in KDR/β-actin mRNA ratios between placental tissue of premature and term deliveries.
In pregnancies that were complicated by preeclampsia, placental VEGF/β-actin mRNA ratio and both receptor mRNA levels (flt-1/β-actin and KDR/β-actin) were significantly higher than in gestational-age matched control pregnancies (Fig 3, Table II ). Similar results were found for normalization to PBGD gene expression (Table II) . Placental weights and newborn infant weights were slightly lower than in control pregnancies (Table I) , and a significant association to VEGF/β-actin and VEGFR/β-actin ratios was not evident either.
In deliveries that were complicated by birth asphyxia, significantly higher VEGF/β-actin and KDR/β-actin mRNA ratios were present in placentas from severe asphyxiated newborn infants, which resulted in HIE (grade 2-3, n = 5 infants) than in placental tissues of mild birth asphyxia (grade 0-1, P < .005, Fig 3, Table III ). There was no difference in flt-1/β-actin mRNA expression. VEGF/β-actin and KDR/β-actin mRNA levels did not correlate with initial routine biochemical markers of hypoxia (umbilical blood pH and base deficit). However, three of the five newborn infants with severe birth asphyxia had a history of prenatal pathologic data (cardiotocogram decelerations, intrauterine growth retardation, severe anemia from placental bleeding).
Immunohistologic examination revealed protein expression of VEGF mainly in vascular endothelial cells and in villous trophoblasts. Similar to the mRNA data, VEGF protein was detected in higher concentrations in placental tissues, especially in the vascular endothelial cells, of birth asphyxia and preeclampsia cases compared with control subjects (Fig 4) . Immunohistologic results are summarized in Table IV .
Comment
In response to hypoxia, we found an augmented mRNA expression of VEGF/VEGFR in BeWo cells as has been shown in vitro in similar experiments 13, 19 and in other cell lines 5,9,20 and in vivo. 21 , 22 Gerber et al 23 showed Placental VEGF mRNA expression in pregnancies that were complicated by preeclampsia or birth asphyxia compared with healthy control subjects. Asterisk, Probability value of <.05 by one-way analysis of variance; two asterisks, Probability value of <.01 by one-way analysis of variance. a differential transcriptional regulation of the two receptors with an increase of flt-1 gene expression in human umbilical vein endothelial cells by hypoxia, but no significant changes in KDR gene expression. Others found hypoxia-induced KDR expression, 20, 24 but no flt-1 up-regulation in human umbilical vein endothelial cells. 5, 15, 24 Different tissue-specific mechanisms and different experimental conditions might be possible explanations for these differences. 5 As suggested by our results, acute severe hypoxia/ischemia stimulates human placental VEGF protein, VEGF mRNA, and KDR mRNA expression in vivo. By the activation of vasodilatation, endothelial cell proliferation, and survival, 2,12 VEGF binding to KDR is assumed to be involved in the paracrine vascular and cell survival regulation mechanisms that are activated by acute tissue hypoxia/ischemia. As our data show, placental tissues of acute birth asphyxia without apparent prenatal complications and with mild/no postnatal HIE of the newborn infant had lower VEGF mRNA levels than those of the 5 severe asphyxiated neonates, with HIE 2-3. This might indicate prenatal primary or secondary clinically relevant placental hypoxygenation in neonates with HIE 2-3. With regard to the expected poorer neurologic outcome in neonates with more severe HIE, changes in the VEGF system gene expression might provide an additional marker for the severe forms of HIE. Long-term studies will have to relate VEGF protein and gene expression to the longterm outcome of these patients.
In contrast with the findings in acute placental hypoxia, in placental tissue of women with preeclampsia, which was exposed chronically to impaired oxygen delivery, an augmented expression of placental flt-1/β-actin mRNA and elevated VEGF/β-actin and KDR/β-actin mRNA expression were observed. These results indicate a functional role of the VEGF system in the adaptation mechanisms of neovasculogenesis in response to the compromised placental oxygen delivery in preeclampsia. As recently shown, 8 increased placental expression of flt-1 mRNA in preeclampsia is found predominantly in syncytiotrophoblasts, whereas KDR mRNA is expressed in the vascular endothelial cells of the placenta. Functionally, hypoxic-ischemic-induced VEGF mRNA and flt-1 mRNA up-regulation activates branching angiogenesis, which is a well-known mechanism of neovasculogenesis in preeclampsia and other conditions of pathologic fetal angiogenesis, such as intrauterine growth retardation. 8, 10 Using immunohistochemistry, Simmons et al 25 found a correlation of increased placental VEGF protein expression and uterine artery resistance index that indicated that VEGF is involved in the compensatory vascular regulation mechanisms in preeclampsia. Similar to our results, VEGF protein was highly expressed in the decidual trophoblast and villous syncytiotrophoblast in preeclampsia. As found by Immunohistochemistry (CD31 staining, Immunhistologic staining for VEGF expression in term placental tissue of severe birth asphyxia (A, gestational age: 40 weeks) that resulted in neonatal HIE grade 2 compared with preeclampsia (B, gestational age: 39 weeks) and a gestational agematched control (C, gestational age: 40 weeks). Note that endothelial VEGF expression (arrows) is markedly higher in severe birth asphyxia and preeclampsia than in the gestational age-matched control.
data not shown), there was no evidence that the difference in VEGF expression is the result of a different density of blood vessels in hypoxic and control tissues.
Whether the up-regulation of VEGF receptor mRNA in birth asphyxia and in preeclampsia is caused by different mechanisms remains to be examined. Compared with the prolonged placental hypoxygenation and impaired perfusion in preeclampsia, our data on acute birth asphyxia show short-term effects of hypoxia in vivo. Thus, the different regulation of receptor mRNA might be a time-dependent phenomenon. Alternatively, the diverging increase of flt-1 mRNA and KDR mRNA in preeclampsia and birth asphyxia could be a VEGF-mediated effect rather than a directly hypoxia-induced mechanism. As shown in vitro, VEGF itself modulates the expression of its receptors under normoxic conditions in a time-and dose-dependent manner. 20, 26, 27 In summary, similar to chronically impaired placental oxygenation in preeclampsia, more acute tissue hypoxia, which is present in severe birth asphyxia, activates VEGF mRNA and protein up-regulation. The degree of perinatal asphyxia seems to determine whether the VEGF system is activated, which turns it into a possible marker system for the impact of perinatal hypoxygenation.
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